<DOC>
	<DOC>NCT00527033</DOC>
	<brief_summary>Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo</brief_summary>
	<brief_title>A Study of YM178 in Patients With Symptomatic Overactive Bladder</brief_title>
	<detailed_description>To investigate the dose-response relationship of YM178 in terms of efficacy, safety and tolerability, and also the superiority of YM178 over placebo.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients over 20 years suffering from overactive bladder Pregnant and breastfeeding women Any clinically significant abnormal conditions which in the opinion of the investigator makes the patient unsuitable for the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>YM178</keyword>
	<keyword>Urinary Bladder, Overactive</keyword>
</DOC>